Scinai Immunotherapeutics (SCNI)

• Market cap: $2.45M
• 1 day: 0.37%
• 5 days: -0.48%
• 1 month: -1.72%
• 3 months: -11.05%
• 6 months: -51.2%
• Year to date: -3%
• 1 year: -79.19%
• 5 years: -99.83%
• 10 years: -99.82%
• Sector: Healthcare
• Industry: Biotechnology

About: Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Employees: 31